Longitudinal SARS‐CoV‐2 seroprevalence in Portugal and antibody maintenance 12 months after infection

During the COVID‐19 pandemic, Portugal has experienced three distinct SARS‐CoV‐2 infection waves. We previously documented the prevalence of SARS‐CoV‐2 immunity, measured by specific antibodies, in September 2020, 6 months after the initial moderate wave. Here, we show the seroprevalence changes 6 months later, up to the second week of March 2021, shortly following the third wave, which was one of the most severe in the world, and 2 months following the start of the vaccination campaign. A longitudinal epidemiological study was conducted, with a stratified quota sample of the Portuguese population. Serological testing was performed, including ELISA determination of antibody class and titers. The proportion of seropositives, which was 2.2% in September 2020, rose sharply to 17.3% (95% CI: 15.8–18.8%) in March 2021. Importantly, circulating IgG and IgA antibody levels were very stable 6 months after the initial determination and up to a year after initial infection, indicating long‐lasting infection immunity against SARS‐CoV‐2. Moreover, vaccinated people had higher IgG levels from 3 weeks post‐vaccination when compared with previously infected people at the same time post‐infection.

[1]  M. Mota,et al.  Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal , 2021, Emerging infectious diseases.

[2]  P. Weihe,et al.  SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands , 2021, Open forum infectious diseases.

[3]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[4]  M. van Boven,et al.  Controlling the pandemic during the SARS-CoV-2 vaccination rollout , 2021, Nature Communications.

[5]  C. Donnelly,et al.  REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England , 2021, medRxiv.

[6]  Yongsheng Wu,et al.  Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study , 2021, The Lancet Microbe.

[7]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection , 2021, Science.

[8]  M. Veldhoen,et al.  Endemic SARS-CoV-2 will maintain post-pandemic immunity , 2021, Nature Reviews Immunology.

[9]  M. Veldhoen,et al.  Academic labs supporting COVID‐19 diagnostics , 2021, European journal of immunology.

[10]  M. V. van Zelm,et al.  Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence , 2020, Science Immunology.

[11]  S. Lee,et al.  Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection , 2020, Emerging infectious diseases.

[12]  M. Hernán,et al.  Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study , 2020, BMJ.

[13]  J. Weitz,et al.  Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies , 2020, medRxiv.

[14]  C. Cordon-Cardo,et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.

[15]  M. Dake,et al.  Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity , 2020, Immunity.

[16]  P. G. Choe,et al.  Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection , 2020, Emerging infectious diseases.

[17]  A. Iafrate,et al.  Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients , 2020, Science Immunology.

[18]  B. Horta,et al.  SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys , 2020, The Lancet Global Health.

[19]  G. Rodger,et al.  Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison , 2020, The Lancet Infectious Diseases.

[20]  M. Veldhoen,et al.  Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset , 2020, medRxiv.

[21]  P. Weihe,et al.  Seroprevalence of SARS-CoV-2–Specific Antibodies, Faroe Islands , 2020, Emerging infectious diseases.

[22]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[23]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[24]  A. Flahault,et al.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.

[25]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[26]  F. Yu,et al.  Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset , 2020, European Respiratory Journal.

[27]  J. Ioannidis,et al.  The infection fatality rate of COVID-19 inferred from seroprevalence data , 2020, medRxiv.

[28]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[29]  Kaijun Jiang,et al.  SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup , 2020, Current protocols in microbiology.

[30]  Kyoung-Ho Song,et al.  MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015 , 2017, Emerging infectious diseases.

[31]  G. Gao,et al.  T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV , 2016, Antiviral Research.

[32]  Z. Memish,et al.  Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Yuxian He,et al.  Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients , 2011, Scandinavian journal of infectious diseases.

[34]  Wei Liu,et al.  Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome , 2006, The Journal of infectious diseases.

[35]  S. Reed The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: Evidence of heterogeneity among 229E‐related strains , 2005, Journal of medical virology.

[36]  P. Hsueh,et al.  Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS‐associated coronavirus , 2004, Clinical Microbiology and Infection.

[37]  K L Jackson,et al.  Confidence intervals for weighted proportions. , 1994, Statistics in medicine.

[38]  D. Tyrrell,et al.  The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.

[39]  K. Callow Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection , 1985, Journal of Hygiene.

[40]  D. Tyrrell,et al.  Effects of a "new" human respiratory virus in volunteers. , 1967, British medical journal.

[41]  S. Tribler,et al.  Prevalence of SARS-CoV-2 antibodies in Denmark 2020: results from nationwide, population-based sero-epidemiological surveys , 2021 .

[42]  B. Gladen,et al.  Estimating prevalence from the results of a screening test. , 1978, American journal of epidemiology.